Instylla’s Embrace HES Approved for Peripheral Arterial Bleeds

October 29, 2026—Instylla, Inc., a developer of resorbable embolics for peripheral vascular embolization, announced that the FDA has approved an expanded indication for the company’s Embrace hydrogel embolic system (HES) to include embolization of peripheral arterial bleeds in vessels ≤ 6 mm.

BD’s Liverty TIPS Stent Graft for Portal Hypertension Launched in the United States

October 28, 2026—BD (Becton, Dickinson and Company) announced the launch of the Liverty transjugular intrahepatic portosystemic shunt (TIPS) stent graft to treat portal hypertension in the United States.

Siemens’ Ultrasound Business Shifts Focus to Procedural Imaging and Image-Guided Therapy

October 28, 2026—Siemens Healthineers announced the strategic focus of its ultrasound business is shifting to procedural imaging and image-guided therapy.

AdvaMed Submits Recommendations to CMS to Strengthen RAPID Coverage Pathway 

October 27, 2026—AdvaMed, the Advanced Medical Technical Association, announced it recommended refinements to the Centers for Medicare & Medicaid Services (CMS) that the agency could make to help its proposed Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway deliver more timely access to breakthrough medtech for Medicare beneficiaries.

United Kingdom Will Continue to Recognize European CE Mark for Medical Devices

October 26, 2026—The United Kingdom’s Medicines and Healthcare Agency (MHRA) announced that the government confirmed it will continue to accept CE Mark-approved medical devices on a long-term basis.

IceCure Begins Postmarket Study of ProSense Cryoablation for Breast Cancer

October 26, 2026—IceCure Medical Ltd., developer of minimally invasive cryoablation technology, announced the enrollment of the first two patients at United States clinical sites in the postmarketing study evaluating ProSense cryoablation for the local treatment of low-risk breast cancer.

SPIRARE II Results Published for Jupiter’s Vertex Thrombectomy System

October 20, 2026—Jupiter Endovascular, Inc. announced that the full results of the SPIRARE II pivotal trial, evaluating the company’s Vertex thrombectomy system in patients with acute, intermediate-risk pulmonary embolism (PE), were published in EuroIntervention by Sameh Sayfo, MD, et al.

Penumbra’s CAVT Technology Cleared for DVT Indication

October 20, 2026—Penumbra, Inc. announced that the FDA has granted clearance for the treatment of deep vein thrombosis (DVT) to the company’s Lightning computer-assisted vacuum thrombectomy (CAVT) technology.